in 10 YEARS
WHAT COMES NEXT?
I believe that personalized or precision medicine will become
more popular in the field of interventional oncology. For example, currently, we use cytotoxic agents at the time of TACE in all HCC patients. However, those drugs are not personalized. In the future, I believe that more personalized drugs will be used at the time of TACE, based on cancer/patient genomic information. Similarly, the decision of optimal ablation therapy will be also made based on genomic information.
— HARUYUKI TAKAKI, MD
7. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679–689.
8. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committee. Obesity and Kidney Disease: Hidden Consequences of the Epidemic. Can J Kidney Health Dis 2017;4:2054358117698669.
9. Jehan S, Zizi F, Pandi-Perumal SR, et al. Obstructive sleep apnea and obesity: Implications for public health. Sleep Med Disord 2017;1.
10. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26:883–896.
11. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev 2011;12:e426–37.
12. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Body Fatness and cancer—Viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794–798.
13. Bawudun D, Xing Y, Liu WY, et al. Ghrelin suppression and fat loss after left gastric artery embolization in canine model. Cardiovasc Intervent Radiol. 2012.
14. Kipshidze N, Archvadze A, Bertog S, Leon MB, Sievert H. Endovascular bariatrics: First in humans study of gastric artery embolization for weight loss. JACC: Cardiovascular Interventions 2015.
15. Bai ZB, Qin YL, Deng G, Zhao GF, Zhong BY, Teng GJ. Bariatric Embolization of the Left Gastric Arteries for the Treatment of Obesity: 9-Month Data in 5 Patients. Obes Surg. 2018;28(4):907-915. doi:10.1007/ s11695-017-2979-9
16. Zaitoun MMA, Basha MAA, Hassan F, et al. Left gastric artery embolization in obese, prediabetic patients: A pilot study. J Vasc Interv Radiol 2019;30:790-796.
17. Syed MI, Morar K, Shaikh A, et al. Gastric artery embolization trial for the lessening of appetite nonsurgically (GET LEAN): Six-month preliminary data. J Vasc Interv Radiol. 2016 Oct;27:1502-1508.
18. Arepally A, Barnett BP, Montgomery E, Patel T. Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: Initial experience. Radiology 2007.
19. Weiss CR, Akinwande O, Paudel K, et al. Clinical safety of bariatric arterial embolization: preliminary results of the BEAT Obesity Trial. Radiology 2017 May;283:598–608.
20. Kordzadeh A, Lorenzi B, Hanif MA, Charalabopoulos A. Left Gastric Artery Embolisation for the Treatment of Obesity: a Systematic Review. Obes Surg. 2018;28(6):1797-1802.
21. Weiss CR, Abiola GO, Fischman AM, et al. Bariatric embolization of arteries for the treatment of obesity (BEAT Obesity) trial: Results at 1 Year. Radiology 2019 Jun;291:792–800.
22. Kim DJ, Raman HS, Salter A, et al. Analysis of weight changes after left gastric artery embolization in a cancer-naive population. Diagn Interv Radiol. 2018;24(2):94-97.
23. Elens S, Roger T, Elens M, et al. Gastric embolization as treatment for overweight patients; efficacy and safety. Cardiovasc Intervent Radiol. 2019;42:513–519.
24. Gunn AJ, Oklu R. A preliminary observation of weight loss following left gastric artery embolization in humans. J Obes. 2014;2014:185349.
25. Takahashi EA, Takahashi N, Reisenauer CJ, Moynagh MR, Misra S. Body composition changes after left gastric artery embolization in overweight and obese individuals. Abdominal Radiology 2019;44:2627–2631.
26. Paxton BE, Kim CY, Alley CL, et al. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. Radiology 2013;266:471–479.
27. Fu Y, Weiss CR, Paudel K, et al. Bariatric Arterial Embolization: Effect of Microsphere Size on the Suppression of Fundal Ghrelin Expression and Weight Change in a Swine Model. Radiology. 2018;289(1):83–89.
28. Vairavamurthy J, Anders R, Beh C, Mao HQ, Wang TH, Kraitchman D, Weiss C. Identifying the target vessel size for bariatric arterial embolization: A comparative histologic analysis of swine and human fundi.
29. Weiss CR, Fu Y, Beh C, et al. Bariatric erterial embolization with calibrated radiopaque microspheres and an antireflux catheter suppresses weight gain and appetite-stimulating hormones in swine. J Vasc Interv Radiol. 2020 Sep;31:1483–1491.
30. Beh CW, Fu Y, Weiss CR, et al. Microfluidic- prepared, monodisperse, X-ray-visible, embolic microspheres for non-oncological embolization applications. Lab Chip 2020;20:3591–3600.
31. Reddy VY, Neuzil P, Musikantow D. Sramkova P, Rosen R, Kipshidze N, Kipshidze N, Fried M. Transcatheter bariatric embolotheraphy for weight reduction in obesity: A single-blind, sham-procedure, randomized controlled trial. Journ Am Cardiol. 2020;76(20):2305–2317.
1981
The embolization technique for spleen trauma is created.
1982
Transjugular intrahepatic portosystemic shunt (TIPS) is create to improve blood flow in damaged livers from conditions such as cirrhosis and hepatitis C.
Dilators for interventional urology, percutaneous removal of kidney stones are created.
10 IRQ | SPRING 2021 SUPPLEMENT
1983
SCR changes its name to the Society of Cardiovascular and Interventional Radiology (SCVIR).
The balloon-expandable stent (peripheral) is created; the same model which is still used today.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20
